• Due to advances in treatment and early detection, nearly 90% of women with breast cancer are living at least 5 years following their diagnosis o Living longer, there is increased risk for the development of longterm, late effects of cancer treatment o Cardiotoxicity may arise either during or after breast cancer treatments such as anthracyclines and/or trastuzumab• Recent evidence has suggested the potential for statin use, a lipidlowering drug, during treatment to mitigate the risk of cardiotoxicity in patients receiving cardiotoxic chemotherapy• Research Question: Does statin use lower the risk of cardiotoxicity among breast cancer patients who receive treatment with anthracyclines and/or trastuzumab
